Title
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease
Phase
Phase 1Lead Sponsor
AzidusStudy Type
InterventionalStatus
Active, not recruitingIndication/Condition
Huntington DiseaseIntervention/Treatment
Cellavita HD Lower Dose Cellavita HD Higher doseStudy Participants
6Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, non-randomized, phase I study in which participants with Huntington's Disease will receive three intravenous injections and will be followed for 5 years to evaluate safety and tolearability of product and preliminary evidence of effectiveness.
This is a first-in-human, non-randomized, phase I study in which participants with HD will receive three intravenous injections of one of two doses of the investigational product, one every month for three months. Safety evaluation data will be composed by the register of adverse events (including type, frequency, intensity, seriousness, severity, and action taken related to the investigational product), could be include changes in vital signs, physical and medical evaluations, laboratory or serology tests and electrocardiogram (ECG), and by the incidence of benign and malign neoplasms. Preliminary evidence of efficacy will be evaluated by global clinical improvement (CIBIS) and evolution of disease improvement (motor, cognitive and behavioral degradation) through Unified Huntington's Disease Rating Scale - UHDRS and inflammatory markers: IL-4, IL-6, IL-10 (interleukin IL) e TNF-alpha (tumoral necrosis factor alpha). CNS improvement will be assessed by magnetic resonance imaging (MRI). Fluctuation in suicide tendency grade will be evaluated by Hamilton Depression Rating Scale (HDRS).The immunological response of HD product over the administration period will be evaluated by CD4+ and CD8+ proliferation and inflammatory markers release.
Participants who show evidence of loss of clinical benefit achieved over the course of treatment verified through worsening greater or equal to that expected for the natural course of the disease on motor, cognitive, behavioral and functional capacity symptoms assessed by the UHDRS scale, will receive additional doses of the product as long as there is clinical benefit at the Investigator's discretion and/or until the product is marketed. The same dose used by the subject during the treatment period will be administered throughout the period of additional doses.
The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells/weight range per administration of Cellavita HD (n= 3) .
Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells/weight range per administration of Cellavita HD (n= 3).
Inclusion Criteria: Sign and date ICF; Ability to follow instructions as well as ability to understand and fulfill the study requirements correctly; Male participant aged ≥ 21 and ≤ 65; Participants who submit medical report (PCR) attesting Huntington's disease with a number of CAG repeats on chromosome 4, greater than or equal to 40 and less than or equal to 50 (if the participant has not performed the examination and/or if he does not have the report available, a new exam should be done); Score 5 points or more in motor assessment UHDRS scale (Unified Huntington's Disease Rating Scale) at the time of enrollment; Score between 8 and 11 points in the functional capacity of the UHDRS scale at the time of enrollment. Exclusion Criteria: Participation within 12 months in any clinical trial; Any medical observation data (clinical and physical) that medical research judge as a risk for subject if enrollment at the study; Any laboratory exam data that medical research judge as a risk for subject if enrollment at the study; Juvenile Huntington disease diagnosis; History of epilepsy; Diagnostic of major cognitive impairment; Active decompensated psychiatric disease; Current or prior history of neoplasia; Current history of gastrointestinal, hepatic, renal, endocrine, pulmonary, hematologic, immune, metabolic pathology or severe and uncontrolled cardiovascular disease; Diagnostic of any active infection, be it viral, bacterial, fungal, or caused by another pathogen; Participants who have contraindication to undergo any of the tests performed in this study, for example, have pacemakers or surgical clip; History of alcohol or illegal drugs abusers; History of 1 or more episodes of suicide in the two years before Visit V-4; Active smoker or have stopped smoking less than six months prior to enrollment; Test positive in at least one of the serological tests: HIV 1 and 2 (Anti-HIV-1,2), HTLV I and II, HBV (HBsAg, anti-HBc), HCV (anti-HCV-Ab) and VDRL (Treponema pallidum); History of drug allergy, including contrasts for imaging, or bovine products; In use or expected use of immunosuppressive drugs or prohibited medicines for the first three months after the first administration of the investigational product; Any clinical changes that is interpreted by the medical researcher as a risk to participant's enrollment.
